Notice of Allowability	Application No.	Applicant(s)	
	10/089,796	BOLOGNA ET AL.	
	Examiner	Art Unit	í
	Konata M. George	1616	
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate commu GHTS. This application is s	this application. If not included unication will be mailed in due co	urse. THIS
1. \boxtimes This communication is responsive to <u>Amendment filed May</u>	<u>/ 26, 2004</u> .		
2. The allowed claim(s) is/are 13-22 and 38-50 (renumbered)	<u>1-23)</u> .		
3. The drawings filed on are accepted by the Examine	r.		
 4. Acknowledgment is made of a claim for foreign priority una) All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority documents have Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	been received. been received in Applicatio	n No	n from the
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		a reply complying with the requi	rements
5. A SUBSTITUTE OATH OR DECLARATION must be subministration (PTO-152) which give			TICE OF
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") mus (a) ☐ including changes required by the Notice of Draftspers 1) ☐ hereto or 2) ☐ to Paper No./Mail Date (b) ☐ including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the property of the property	on's Patent Drawing Reviews S Amendment / Comment or 84(c)) should be written on the header according to 37 CF	in the Office action of ne drawings in the front (not the ba R 1.121(d).	
 DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT I 			e tne
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview St Paper No./ 8), 7. ☐ Examiner's	formal Patent Application (PTO-1 ummary (PTO-413), Mail Date Amendment/Comment Statement of Reasons for Allowa	·

Application/Control Number: 10/089,796

Art Unit: 1616

DETAILED ACTION

Claims 13-22 and 38-50 are pending in this application.

Action Summary

- 1. Examiner acknowledges the cancellation of claims 1-10, 36 and 37. Therefore, any and all rejections directed towards these claims are hereby withdrawn.
- 2. Examiner acknowledges the addition of claims 39-50.
- 4. The rejection of claims 13-19 and 22 under 35 U.S.C. 102(e) as being anticipated by Harrison et al. as evidenced by Peterson et al. is hereby withdrawn in response to applicants arguments.
- 5. The rejection of claim 38 under 35 U.S.C. 102(e) as being anticipated by Harrison et al. as evidenced by Peterson et al. is hereby withdrawn as it was improperly applied.
- 6. The rejection of claims 20 and 21 under 35 U.S.C. 103(a) as being anticipated by Harrison et al. in view of Peterson et al. is hereby withdrawn in response to applicants arguments.

Application/Control Number: 10/089,796 Page 3

Art Unit: 1616

Statement of Reasons for Allowance

7. The following is an examiner's statement of reasons for allowance:

The claims are allowable over the cited prior art because the prior art does not teach, disclose nor make obvious a method of treating endometriosis by administering a composition comprising a β -adrenergic agonist and a pharmaceutically acceptable bioadhesive carrier. The closet prior art is Harrison et al. (6,197,327) and Peterson et al. (6,207,696). Together both patents teach a composition comprising β -adrenergic agonists and biocompatible excipients for the treatment of dysmenorrhea. Dysmenorrhea is defined as the pain associated with endometriosis. Endometriosis is a condition that is characterized by the presence of functioning ectopic endometrial glands and stroma outside the uterine cavity. Therefore, the prior art does not teach not treating the condition of endometriosis, but treating the pain associated with endometriosis.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

8. Claims 13-22 and 38-50 are allowed.

Application/Control Number: 10/089,796 Page 4

Art Unit: 1616

Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konata M. George, whose telephone number is (571) 272-0613. The examiner can normally be reached from 8AM to 5:30PM Monday to Thursday, and on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached at (571) 272-0887. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Konata M. George

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600